^
BIOMARKER:

TP53 mutation

i
Other names: TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
TP53 mutation
Acute Myelogenous Leukemia
venetoclax
Resistant
:
B
SOHO 2022 - 6 days - (New C3)
TP53 mutation
Chronic Myelomonocytic Leukemia
venetoclax
Sensitive
:
C1
SOHO 2022 - 6 days - (New C3)
TP53 mutation
Myelodysplastic Syndrome
venetoclax
Sensitive
:
C2
SOHO 2022 - 6 days - (New C3)
TP53 mutation
Myelodysplastic Syndrome
GS-4721
Sensitive
:
C3
SOHO 2022 - 6 days - (New C3)
TP53 mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
B
ESMO 2022 - 3 weeks - (New C3)
TP53 mutation
Chronic Lymphocytic Leukemia
venetoclax + obinutuzumab
Sensitive
:
A1
TP53 mutation
Chronic Lymphocytic Leukemia
venetoclax
Sensitive
:
A1
TP53 mutation
Chronic Lymphocytic Leukemia
rituximab + idelalisib
Sensitive
:
A1
TP53 mutation
Chronic Lymphocytic Leukemia
acalabrutinib
Sensitive
:
A1
TP53 mutation
Chronic Lymphocytic Leukemia
idelalisib + ofatumumab
Sensitive
:
A1
TP53 mutation
Chronic Lymphocytic Leukemia
rituximab + alemtuzumab
Sensitive
:
A2
TP53 mutation
Chronic Lymphocytic Leukemia
venetoclax + rituximab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive
:
A2
TP53 mutation
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
rituximab
Sensitive
:
A2
TP53 mutation
Chronic Lymphocytic Leukemia
ibrutinib
Sensitive
:
A2
TP53 mutation
Chronic Lymphocytic Leukemia
ofatumumab
Resistant
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
ibrutinib
Sensitive
:
A2
TP53 mutation
Chronic Lymphocytic Leukemia
idelalisib
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
ofatumumab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
idelalisib
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
venetoclax
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
rituximab + idelalisib
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
duvelisib
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
venetoclax + rituximab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
obinutuzumab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
alemtuzumab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
rituximab + alemtuzumab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
venetoclax + obinutuzumab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
acalabrutinib
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
obinutuzumab + acalabrutinib
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
lenalidomide
Sensitive
:
A2
TP53 mutation
Chronic Lymphocytic Leukemia
lenalidomide
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
rituximab + lenalidomide
Sensitive
:
A2
TP53 mutation
Chronic Lymphocytic Leukemia
rituximab + lenalidomide
Sensitive
:
A2
TP53 mutation
Chronic Lymphocytic Leukemia
rituximab
Sensitive
:
A2
TP53 mutation
Chronic Lymphocytic Leukemia
alemtuzumab
Sensitive
:
A2